Zydus life sciences is a well-known player and among the top 5 companies in the pharma space. The company has a solid pipeline of biologics and vaccines.
Fundamentally, the company has beat quarterly earnings estimates by an average of 10% for 3 straight quarters. The company has reduced debt and has been paying out good dividends also.
YoY quarterly revenue, margins, and profit have shown good positive trend.
Technically, the price hit new 52-week highs recently. However there are two major resistance zones above current price as shown in the chart.
Nevertheless, the price volume action is favorable for now with strong uptrend in recent times.
Compared to benchmark index, the stock is showing relative strength which in turn is also in an uptrend.
Source: tickertape.in, screener.in
Disclaimer: This is for informational purposes only. It is not intended to be a solicitation or an offer to buy or sell any security or instrument or to participate in any particular trading strategy. The views and opinions expressed here are personal. The information contained here has been obtained from sources believed to be reliable but is not necessarily complete, and its accuracy cannot be guaranteed. I may have positions in the securities or instruments shared as ideas. Do your own research OR consult a financial advisor for personalized investment advice.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.